Tag Archives: Apple

Apple Advances Non-Invasive Glucose Monitor; Tandem, Madrigal, Alnylam, and Teladoc Q4 ’22 Earnings; ATTD 2023 Key Press Releases Day 2

A series of cardiometabolic-related news items have been observed from Apple, Tandem, Madrigal, Alnylam, Teladoc, Glooko, Biora, and Diabeloop. Below, FENIX provides highlights and insights into the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Apple Watch Reportedly Faces Glucose Monitoring Delays; Diabeloop to Adapt AID Software for Insulin Pens; MediciNova to Initiate Ph2 NAFLD Trial

Three cardiometabolic-related news items have been observed: It has been reported that Apple has been experiencing development problems with its blood glucose monitoring feature for its Apple Watch (view article); Diabeloop announced plans to adapt its AID software for insulin pens via a new smartphone app (DBL-4pen); and, MediciNova, Inc., announced FDA has completed its review of the company’s Ph2 clinical trial protocol to evaluate MN-001 (tipelukast) for the treatment of patients with NAFLD, T2DM, and hypertriglyceridemia. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Apple Watch 8 Reportedly Set to Include BGM; Lifescan Launches OneTouch Solutions; Xeris and Merck Collaboration; Dario Partners with New Employer Group; Tidepool Period Project Receives Financial Support

A series of cardiometabolic-related news items have been observed: New reports suggest the Apple Watch Series 8 may include a blood glucose reader (view article); Lifescan announced the launch of OneTouch Solutions; Xeris announced a collaboration agreement with Merck to leverage Xeris’s injection suspension technology “for the purpose of engineering ultra-high concentration, ready-to-use [mAb] formulations”; Dario announced a new agreement with a US national employer; and Tidepool announced it has received financial support from Amazon Web Services (AWS) for Tidepool Period Project. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Apple Cites T1DM Omnipod Patient Story at Tuesday Event; Jardiance Post-MI Trial (EMPACT-MI) Receives FDA FTD; Adocia Topline Results from M1Pram Ph1b Trial Extension; Welldoc/UMD Employs AI to Identify Digital Health Habits; Oramed’s Positive Diabetes Market Survey Results; Diamyd Receives $13.9M Towards Companion Medical Shares

A series of diabetes-related news items have been observed: Apple featured a T1DM patient story during the Apple Watch portion of its event; BI/Lilly announced Jardiance has received Fast Track designation for its EMPACT-MI study; Adocia announced positive topline results from its Ph1b M1Pram extension study in PWT1D; Welldoc and the University of Maryland’s Center for Health Information and Decision System (CHIDS) announced findings from a user engagement analysis; Oramed announced results from a diabetes market survey; and Diamyd received $13.9M from its divestment in Companion Medical. Below, FENIX provides highlights and insights from the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Thoughts on OneDrop/Apple BGM Distribution

One Drop recently announced that its BGM platform is now available in select US Apple stores. The One Drop BGM platform, which includes a mobile app, integrates with Apple HealthKit and is able to send data directly to an iPhone or Apple Watch. This is One Drop’s second large distribution agreement in 2019. In March, One Drop announced a partnership with Amazon to be part of Amazon’s Choice. Below, FENIX provides thoughts on why the distribution agreement makes sense for both One Drop and Apple.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.